This statistic shows the prevalence of any oral human papillomavirus (HPV) in U.S. adults according to the National Health and Nutrition Examination Survey from 2011 to 2014. According to the survey, Non-Hispanic Black participants had the highest prevalence of oral HPV, while Non-Hispanic Asian participants had the lowest prevalence of oral HPV. For the total population, the prevalence of oral HPV was 7.3 percent.

This dataset presents the footprint of the percentage of girls who were fully immunised against human papillomavirus (HPV). The data spans the financial years 2012-2016 and is aggregated to Statistical Area Level 4 (SA4) from the 2011 Australian Statistical Geography Standard (ASGS).

HPV is a common sexually transmitted infection. It is estimated that more than four out of five people will have an HPV infection at some point in their lives. Although often asymptomatic, HPV infection can cause a wide range of cancers, including cervical cancer, and other conditions such as genital warts. The Australian Government introduced the school-based National HPV Vaccination Program in 2007 for adolescent girls, and extended it to include boys in January 2013. The data were sourced from the National HPV Vaccination Program Register (HPV Register), which is operated by the Victorian Cytology Service. The HPV Register records information about HPV vaccine doses administered under the National HPV Vaccination Program in Australia. The data reported are for girls and boys aged 15 who had received three doses of HPV vaccine by 30 June 2016 (as at 12 August 2017). The Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) for females and males aged 13 at 30 June 2014 was used for the denominator, as this reflects the eligible population at the time most vaccinations were administered.

\t\t\t\t\t\t\t\t\t\t\t\t\tFor further information about this dataset, visit the data source:Australian Institute of Health and Welfare - HPV immunisation rates in 2015-16 Data Tables.

Please note:

• AURIN has spatially enabled the original data using the Department of Health - PHN Areas.

• These data include girls aged 15 who had received three doses of HPV vaccine by 30 June 2013, 2014, 2015 and 2016. Any doses administered after that date are not included and therefore the current coverage in this cohort may be higher than reported here. Only vaccinations reported to the National HPV Vaccination Program Register (HPV Register) are included.

• Girls whose courses are considered to be incomplete according to the Chief Medical Officer guidelines and girls who do not wish their details to be recorded on the HPV Register are excluded.

• Values assigned to "n.p." in the original data have been removed from the data.

This dataset presents the footprint of the percentage of boys who were fully immunised against human papillomavirus (HPV). The data spans the financial years 2014-2016 and is aggregated to 2015 Department of Health Primary Health Network (PHN) areas, based on the 2011 Australian Statistical Geography Standard (ASGS).

HPV is a common sexually transmitted infection. It is estimated that more than four out of five people will have an HPV infection at some point in their lives. Although often asymptomatic, HPV infection can cause a wide range of cancers, including cervical cancer, and other conditions such as genital warts. The Australian Government introduced the school-based National HPV Vaccination Program in 2007 for adolescent girls, and extended it to include boys in January 2013. The data were sourced from the National HPV Vaccination Program Register (HPV Register), which is operated by the Victorian Cytology Service. The HPV Register records information about HPV vaccine doses administered under the National HPV Vaccination Program in Australia. The data reported are for girls and boys aged 15 who had received three doses of HPV vaccine by 30 June 2016 (as at 12 August 2017). The Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) for females and males aged 13 at 30 June 2014 was used for the denominator, as this reflects the eligible population at the time most vaccinations were administered.

\t\t\t\t\t\t\t\t\t\t\t\t\tFor further information about this dataset, visit the data source:Australian Institute of Health and Welfare - HPV immunisation rates in 2015-16 Data Tables.

Please note:

• AURIN has spatially enabled the original data using the Department of Health - PHN Areas.

• These data include boys aged 15 who had received three doses of HPV vaccine by 30 June 2015 and 2016. Any doses administered after that date are not included and therefore the current coverage in this cohort may be higher than reported here. Only vaccinations reported to the National HPV Vaccination Program Register (HPV Register) are included.

• Boys whose courses are considered to be incomplete according to the Chief Medical Officer guidelines and boys who do not wish their details to be recorded on the HPV Register are excluded.

According to the data, around 38.8 percent of girls aged 12 received the HPV vaccine in Italy in 2022. Friuli Venezia Giulia was the region with the lowest figure, with an immunization rate of only 0.7 percent for the considered population. This statistic depicts the human papillomavirus (HPV) immunization rate among female aged 12 years in Italy in 2022, by region.

Cervical cancer is the most common gynecological malignancy and screening for risk factors with early detection has been shown to reduce the mortality. In this study, we aimed to analyze the characteristics and risk factors of human papillomavirus (HPV) infection and precancerous lesions in women and provide clinical evidence for developing strategies to prevent cervical precancerous lesions and cancer in women. Furthermore, we evaluated the influencing factors for high-risk HPV infection. From April 2018 to December 2021, 10,628 women were recruited for cervical cancer screening at Liaoning Cancer Hospital, Shenyang Sujiatun District Women’s and Infants Hospital, Benxi Manchu Autonomous County People’s Hospital, and Shandong Affiliated Hospital of Qingdao University. The study participants were tested to determine if they were HPV-positive (HPV +) or underwent thinprep cytology test (TCT) for atypical squamous cells of undetermined significance (ASCUS) and above. Furthermore, colposcopies and biopsies were performed for the histopathological examination. Finally, 9991 cases were included in the statistical analysis, and the factors influencing HPV infection and those related to cervical cancer and precancerous lesions were analyzed. HPV + infection, high-grade squamous intraepithelial lesion-positive (CINII +) in cervical high-grade intraepithelial neoplasia, and early cervical cancer diagnosis rates were 12.45, 1.09, and 95.41%, respectively. The potential risk factors for HPV were education ≤ high school [odds ratio (OR) = 1.279 (1.129–1.449), P < 0.001], age at initial sexual activity ≤ 19 years [OR = 1.517 (1.080–2.129), P = 0.016], sexual partners > 1 [OR = 1.310 (1.044–1.644), P = 0.020], ASCUS and above [OR = 11.891 (10.105–13.993), P < 0.001], non-condom contraception [OR = 1.255 (1.059–1.487), P = 0.009], and HSIL and above [OR = 1.541 (1.430–1.662), P < 0.001]. Compared with women aged 56–65 and 35–45 years [OR = 0.810 (0.690–0.950), P = 0.010] the HPV infection rate was significantly lower in those aged 46–55 years [OR = 0.79 (0.683–0.915), P = 0.002]. Furthermore, ≤ high school age [OR = 1.577 (1.042–2.387), P = 0.031], not breastfeeding [OR = 1.763 (1.109–2.804), P = 0.017], ASCUS and above [OR = 42.396 (28.042–64.098), P < 0.001] were potential risk factors for cervical cancer and precancerous lesions. In women with HPV infection, ≤ high school education level, initial sexual activity at ≤ 19 years of age, number of sexual partners > 1, ASCUS and above, non-condom contraception, HSIL and above were risk factors for HPV infection. Compared with women aged 56–65 years, those aged 35–45 and 46–55 years had significantly lower HPV infection rates, and high school age and below, non-breastfeeding, and ASCUS and above were all potential risk factors for cervical cancer and precancerous lesions.

Between the years 2012 and 2016, the average annual rate of cervix cancer was 7.2 per 100,000 population. The statistic illustrates the average annual rate of HPV-associated cancers in the U.S. from 2012 to 2016, by type.

National immunisation coverage rates, 2015 to 2020. Human Papillomavirus (HPV) immunisation coverage rates, 2015 to 2017. National immunisation coverage rates, 2015 to 2020. Human Papillomavirus (HPV) immunisation coverage rates, 2015 to 2017.

Statistics Norway (SSB) conducted a survey in the autumn of 2019 on the free HPV vaccine immunization program. The survey was conducted in collaboration with the Norwegian Institute of Public Health (FHI). The purpose of the survey was to obtain information about the reasons why young women chose or did not choose to make use of the free vaccine offer, to what extent the communication strategy and the measures that were put in place contributed to raising knowledge, attitude and/or behavior change, as well as whether there are differences based on education level, income, country of birth, marital status and number of children.

The survey population includes all women born in the period of 1991 to 1996 who are registered as residents in the National Population Register. The vaccine program ensured that these women, in the period 1st of September 2016 to 30th of June 2019, were offered a vaccine against human papillomavirus infection (HPV infection) to prevent cervical cancer. The data collection was carried out entirely on the web. The field period spanned two weeks, from 23rd of September to 7th of October 2019.

In Denmark, younger generations of the population were vaccinated against HPV to a greater extent than the older generations. As of 2018, 92 percent of Danish females between 15 and 24 years had been vaccinated against HPV at least once. For males in the same age group, the share of respondents amounted to 62 percent. In the older age groups, vaccinations were less common, and more women had had the vaccine than men.

In Denmark, free HPV vaccines are provided for girls when they turn 12 years. As of September 2019, the vaccine was also offered for boys turning 12 years.

The global HPV 9-valent vaccine market was valued at USD 3.0 billion in 2024 and is expected to reach USD 6.2 billion by 2033, registering a CAGR of 9.4% during the forecast period of 2025-2033. The market growth is attributed to the increasing prevalence of HPV-associated cancers, rising awareness about HPV vaccination and its benefits, and government initiatives to include HPV vaccination in national immunization programs. Additionally, the development of new and improved HPV vaccines with enhanced efficacy and safety profiles is further driving market growth. The key market segments are application (female population and male population) and type (bivalent vaccine, quadrivalent vaccine, and 9-valent vaccine). The 9-valent vaccine segment is expected to dominate the market during the forecast period due to its comprehensive protection against a wider range of HPV strains. Furthermore, the increasing adoption of HPV vaccination in developing countries, where the burden of HPV-associated diseases is high, is expected to contribute significantly to market growth. Leading market players include Merck Group, GSK, and Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., which are actively involved in research and development to expand their product portfolios and increase their market share.

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector. In the US the total number of HPV vaccine doses delivered annually is likely to grow steadily over the next few years, as more males receive vaccination and Merck’s nine-valent vaccine V503 becomes available in 2015. US market growth will contribute to global growth in the HPV vaccines sector. There is no indication that coverage rates for adolescent girls will increase dramatically over the forecast period, as they have been relatively stable over the past few years. However, a modest increase will likely be achieved following the introduction of V503, which will be accompanied by a marketing and awareness campaign. Read More

Baseline assumptions for key model parameters, and data sources.

Bivariate analysis of uptake rate of HPV vaccine in population.

Cervical cancer is a type of cancer that occurs in the cells of the cervix, which connects the vagina (birth canal) to the upper part of the uterus (Mayo Clinic, 2021). All women are at risk for cervical cancer. It occurs most often in women ages 30 years and older (Centers for Disease Control and Prevention, 2021). Long-lasting infection with certain types of human papillomavirus (HPV) is the main cause of cervical cancer. Almost all cervical cancer cases (99%) are linked to infection with HPV, an extremely common virus transmitted through sexual contact (World Health Organization, 2021). In 2018, an estimated 570,000 women were diagnosed with cervical cancer worldwide, and about 311,000 women died from the disease (World Health Organization, 2021).
In the 8MM, diagnosed incident cases of cervical cancer are expected to increase from 109,891cases in 2020 to 123,846 cases in 2030, at an Annual Growth Rate (AGR) of 1.27%. In 2030, urban China will have the highest number of diagnosed incident cases of cervical cancer in the 8MM, with 83,479 cases, whereas Spain will have the fewest diagnosed incident cases of cervical cancer with 2,147 cases. In the 8MM, the five-year diagnosed prevalent cases of cervical cancer are expected to increase from 394,378 cases in 2020 to 453,614 cases in 2030, at an AGR of 1.50%. GlobalData epidemiologists attribute the increase in the five-year diagnosed prevalent cases and diagnosed incident cases of cervical cancer to changes in the diagnosed incidence and survival rates, and population dynamics in each market. Read More

The HPV Test Reagent Kit market is experiencing robust growth, driven by increasing awareness of HPV infections and their link to cervical cancer, coupled with advancements in diagnostic technologies like fluorescence PCR and molecular hybridization. The market size in 2025 is estimated at $1.5 billion, reflecting a strong CAGR of 8% from 2019 to 2024. This growth is further fueled by rising healthcare expenditure globally, expanding screening programs, particularly in developing nations with high cervical cancer incidence, and the increasing adoption of point-of-care testing to facilitate faster diagnosis and treatment. Key players like Hologic, QIAGEN, and Roche are strategically expanding their product portfolios and geographic reach to capitalize on this expanding market. However, factors such as the high cost of advanced testing technologies and the need for skilled personnel to perform the tests pose some restraint to market growth. The market is segmented by application (hospital, laboratory) and type (Fluorescence PCR, Molecular Hybridization), with Fluorescence PCR currently dominating due to its high sensitivity and specificity. Geographical distribution showcases significant market share in North America and Europe driven by high healthcare infrastructure and early adoption of advanced technologies. However, the Asia-Pacific region is poised for rapid expansion given its large population and rising prevalence of HPV infections. The forecast period (2025-2033) projects continued growth, with the market expected to exceed $2.8 billion by 2033. This growth trajectory is supported by ongoing technological innovations that improve test accuracy, reduce costs, and simplify testing procedures, making HPV screening more accessible in diverse healthcare settings. The development of multi-target HPV tests, capable of detecting a wider range of high-risk HPV types, will further contribute to market expansion. Competition among established players and emerging companies is likely to intensify, leading to increased focus on developing cost-effective, user-friendly, and high-performance HPV test reagent kits.

AimTo investigate the clinical efficacy of population-based treatment of human papillomavirus (HPV) infections with Paiteling.MethodsBetween 1 June 2024 and 31 August 2024, 575 HPV-infected patients attending The First People’s Hospital of Jingzhou gynecology outpatient clinic from October 2020 to December 2023 were retrospectively collected, all of whom were analyzed for HPV subtype infection and the presence or absence of cytomorphological abnormality using HPV-DNA testing and TCT; they were divided into 319 cases in the Paiteling group and 256 cases in the Interferon group, and the patients of both groups were subjected to TCT 1 month after the end of the administration of the medication and HPV review.Results1. The three most frequent subtypes of HPV in this data are HPV 16, HPV 52, and HPV 58, all of which are high-risk types; 2. The results of the post-treatment review of HPV infection showed that the overall effective rate of the Paiteling group was better than that of the Interferon group, and the difference in the cumulative effective rate between the two groups was statistically significant (P < 0.001); 3. Comparative analysis of patients with 14 high-risk types of human papillomavirus in a single infection showed that the overall conversion rate in the Paiteling group was 76.3%, higher than that of the Interferon group, which was 36.7%. The difference was statistically significant (P < 0.001).ConclusionThe overall efficacy of Paiteling for cervical HPV infection is significantly better than that of Interferon, and it is worth promoting its use in the clinic.

BackgroundThe northeastern region of Argentina has the highest age-adjusted cervical cancer mortality rates. Given the strong link between HPV infections and cervical cancer, one of the main interventions is the population-based use of HPV vaccines. However, the acceptability is not very clear in low- and middle-income countries. The purpose of this study was to estimate the level of HPV vaccine acceptance and associated determinants among caregivers of girls in a northeastern city of Argentina.MethodsA school-based survey was conducted in 2015 using a multistage sampling method. The primary sample unit were schools stratified by socioeconomic status selected at random, and caregivers of school girls were interviewed. The acceptability was determined using the adapted Theory of Planned Behavior. We performed logistic regression models to assess associated determinants.ResultsThe study included 347 caregivers. The intention to vaccinate was 59.88%. A positive attitude of caregivers (aOR 4.67; 3.11–7.03) and positive influence of social norms (aOR 1.95; 1.03–3.70) were the main predictors independently associated to the intention to vaccinate against HPV. In contrast, practicing a Christian non-Catholic religion decreased the intention to vaccinate against HPV (OR 0.59; 0.36–0.95). All other factors evaluated were not significantly associated with intention to vaccinate against HPV.ConclusionsThis study shows that evaluating attitudes, normative social beliefs, and perceived self-efficacy regarding HPV vaccination can be of utmost importance for mapping and planning of health-related strategies in developing countries.

The Office for Health Improvement and Disparities (OHID) has published the Public Health Outcomes Framework (PHOF) quarterly data update for May 2022.

The data is presented in an interactive tool that allows users to view it in a user-friendly format. The data tool also provides links to further supporting information, to aid understanding of public health in a local population.

18 indicators have been updated in this release:

• healthy life expectancy and disability-free life expectancy at birth and at 65
• 7 indicators from the health improvement domain including conception rates in teenagers, percentage of looked after children whose emotional wellbeing is a cause for concern, and percentage of physically active adults
• 4 indicators from the health protection domain including the fraction of mortality attributable to particulate air pollution (new method), population vaccination coverage for human papillomavirus (HPV) vaccination coverage for two doses (females 13 to 14 years old) and population vaccination coverage - Meningococcal ACWY conjugate vaccine (MenACWY) (14 to 15 years)
• 5 indicators from the healthcare and premature mortality domain including emergency readmissions within 30 days of discharge from hospital and preventable sight loss

See links to indicators updated document for full details of what’s in this update.

View previous Public Health Outcomes Framework data tool updates.

The human cervicovaginal microbiota resides at an interface between the host and the environment and may affect susceptibility to disease. Puerto Rican women have high human papillomavirus (HPV) infection and cervical cancer rates. We hypothesized that the population structure of the cervicovaginal bacterial and fungal biota changed with cervical squamous intraepithelial lesions and HPV infections. DNA was extracted from cervix, introitus, and anal sites of 62 patients attending high-risk San Juan clinics. The 16S rRNA V4 region and ITS-2 fungal regions were amplified and sequenced using Illumina technology. HPV genotyping was determined by reverse hybridization with the HPV SPF10-LiPA25 kit. HPV prevalence was 84% of which ∼44% subjects were infected with high-risk HPV, ∼35% were co-infected with as many as 9 HPV types and ∼5% were infected with exclusively low-risk HPV types. HPV diversity did not change with cervical dysplasia. Cervical bacteria were more diverse in patients with CIN3 pre-cancerous lesions. We found enrichment of Atopobium vaginae and Gardnerella vaginalis in patients with CIN3 lesions. We found no significant bacterial biomarkers associated with HPV infections. Fungal diversity was significantly higher in cervical samples with high-risk HPV and introitus samples of patients with Atypical Squamous Cells of Undetermined Significance (ASCUS). Fungal biomarker signatures for vagina and cervix include Sporidiobolaceae and Sacharomyces for ASCUS, and Malassezia for high-risk HPV infections. Our combined data suggests that specific cervicovaginal bacterial and fungal populations are related to the host epithelial microenvironment, and could play roles in cervical dysplasia.

BackgroundHuman papillomavirus (HPV) infection is an important carcinogenic infection highly prevalent among many populations. However, independent influencing factors and predictive models for HPV infection in both U.S. and Beijing females are rarely confirmed. In this study, our first objective was to explore the overlapping HPV infection-related factors in U.S. and Beijing females. Secondly, we aimed to develop an R package for identifying the top-performing prediction models and build the predictive models for HPV infection using this R package.MethodsThis cross-sectional study used data from the 2009–2016 NHANES (a national population-based study) and the 2019 data on Beijing female union workers from various industries. Prevalence, potential influencing factors, and predictive models for HPV infection in both cohorts were explored.ResultsThere were 2,259 (NHANES cohort, age: 20–59 years) and 1,593 (Beijing female cohort, age: 20–70 years) participants included in analyses. The HPV infection rate of U.S. NHANES and Beijing females were, respectively 45.73 and 8.22%. The number of male sex partners, marital status, and history of HPV infection were the predominant factors that influenced HPV infection in both NHANES and Beijing female cohorts. However, condom application was not an independent influencing factor for HPV infection in both cohorts. R package Modelbest was established. The nomogram developed based on Modelbest package showed better performance than the nomogram which only included significant factors in multivariate regression analysis.ConclusionCollectively, despite the widespread availability of HPV vaccines, HPV infection is still prevalent. Compared with condom promotion, avoidance of multiple sexual partners seems to be more effective for preventing HPV infection. Nomograms developed based on Modelbest can provide improved personalized risk assessment for HPV infection. Our R package Modelbest has potential to be a powerful tool for future predictive model studies.